Biomea Fusion reports Phase 1 results for oral GLP — 1 drug BMF — 650 showing up to 3.2% weight loss at Day 29

Biomea Fusion reported Phase 1 results for oral GLP-1 drug candidate BMF-650, showing early signs of weight loss activity. Outcomes pointed to consistent short-term weight reduction versus placebo, without detailing specific efficacy measurements. Tolerability looked manageable, with no severe safety events reported in the multiple-dose cohorts over four weeks. Data supported rapid dose escalation toward a target regimen, a potential differentiator versus slower titration approaches in the class. Additional analyses remain underway, with a future medical meeting presentation planned. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via (Ref. ID: 202610131608PRIMZONEFULLFEED9845023) on October 13, 2026, and is solely responsible for the information contained therein. (C)